Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children Maddalena CentanniOmar ZaherLena E. Friberg Original Article Open access 23 May 2024
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia Takahiro KobayashiHonami SatoNaoto Takahashi Original Article 23 May 2024
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice Joshua J. DeppasBrian F. KieselJan H. Beumer Original Article 14 May 2024
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity Yuchen SunYue ChengDaniel L. Hertz Review Article 11 May 2024 Pages: 525 - 539
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer Rui XuXiaowen YangFeiyun Jiang Original Article Open access 07 May 2024
Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers Pengfei DuYao LongYuanwei Jia Original Article 04 May 2024
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients Marziyeh GhorbaniSoha NamaziAli Dehshahri Original Article 27 April 2024
Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer In Hee LeeSoo Jung LeeYee Soo Chae Original Article 23 April 2024
Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia Takumi TsujiKatsuaki YonedaTakeyuki Kohno Short Communication 20 April 2024
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors Claire MillerRoberto SommavillaMarie Cullberg Original Article Open access 20 April 2024
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer Xianping XuYu LiuZhibin Luo Original Article 12 April 2024
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1 Kiyoaki UryuYoshinori ImamuraHironobu Minami Original Article 08 April 2024
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors Noboru YamamotoTakafumi KoyamaToshio Shimizu Correction Open access 31 March 2024
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro Xiangping WuJing Wu Original Article Open access 27 March 2024
Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy Hongjie HuoYu FengQiong Tang Correction Open access 26 March 2024
Pharmacology and pharmacokinetics of tazemetostat Marco OrleniJan H. Beumer Brief Report 23 March 2024 Pages: 509 - 517
Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer Justin C. BrownJeffrey A. MeyerhardtBette J. Caan Short Communication 23 March 2024
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects Sheng MaXin WangHua Zhang Regular Paper 20 March 2024
Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related genes: an in silico analysis with in vitro and vivo validation Lin-jie RuanJu-ying JiaoZhen Chen Original Article Open access 19 March 2024
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers Allison DunnNaoko TakebeJogarao V. S. Gobburu Original Article 14 March 2024
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy Atsushi OgawaHiroshi KawamotoToshimi Kimura Original Article Open access 13 March 2024
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment Nancy H.C. LoosViët BuiAlfred H. Schinkel Original Article 08 March 2024
Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series Takashi MasudaTaro FunakoshiAtsushi Yonezawa Case Report 08 March 2024
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer Wei ZhengWei PengXiaoying Fu Original Article 08 March 2024
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer Koutaro OnoRemi MuraseKen-ichi Fujita Original Article 08 March 2024
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer Guangnan ZongJinlin LiXiuli Guo Short Communication 07 March 2024
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors Colby S. ShemeshYongsheng WangXian Wang Original Article Open access 07 March 2024
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants Romain SechaudHelen GuHans D. Menssen Correction 05 March 2024
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients Jaya Shree Dilli BatchaVikram GotaSurulivelrajan Mallayasamy Original Article Open access 05 March 2024
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors Kadriye Bir YücelUguray AydosOzan Yazıcı Original Article 04 March 2024 Pages: 497 - 507
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy Yan JiSherwin K. B. Sy Review Article 02 March 2024 Pages: 273 - 293
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia Wenqiang QuJialing LuSuning Chen Short Communication 02 March 2024
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data Cedric LauMa Ida Mohmaed AliAlwin D. R. Huitema Original Article Open access 01 March 2024
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital Alyssa GaiettoJohn C PanettaHope D Swanson Original Article 28 February 2024 Pages: 617 - 625
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors Toshihiko DoiShunji TakahashiShinichi Okame Original Article Open access 27 February 2024 Pages: 605 - 616
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype John F. MarcellettiBranimir I. Sikic Original Article 26 February 2024 Pages: 595 - 604
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab Zhuoyuan YuHaifan XuLiqun Chen Original Article 25 February 2024 Pages: 587 - 593
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis Xuan MaZhenou SunHongbo Hu Original Article 21 February 2024 Pages: 575 - 585
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001) Mayumi OzawaJun WatanabeItaru Endo Original Article 19 February 2024 Pages: 565 - 573
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study Andrea René JørgensenMats BueMaiken Stilling Original Article Open access 08 February 2024 Pages: 555 - 564
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study Ahmed O. ELKasarFatma Z. HussienAdel R. Abd-Allah Original Article 07 February 2024 Pages: 541 - 554
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure Vikram MalhiMalgorzata NowickaJiajie Yu Short Communication Open access 02 February 2024
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations Xiaoya MaYujie LiTianbo Jin Original Article 01 February 2024 Pages: 481 - 496
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study Bin FanGhassan K. Abou-AlfaHua Yang Original Article Open access 27 January 2024 Pages: 471 - 479
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells Alexandr N. ChernovAlexandr V. KimOlga V. Shamova Original Article 27 January 2024 Pages: 455 - 469
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants Romain SechaudHelen GuHans D. Menssen Original Article 25 January 2024 Pages: 439 - 453
Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity Qian TanA. M. JoshuaIan F. Tannock Correction 19 January 2024
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells Thamir M. MahgoubEmmet J. JordanDenis M. Collins Original Article Open access 16 January 2024 Pages: 427 - 437
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors Noboru YamamotoTakafumi KoyamaToshio Shimizu Short Communication Open access 11 January 2024
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation Chong-Zhi WangChunping WanChun-Su Yuan Original Article 09 January 2024 Pages: 411 - 425
